Schott Pharma stock edges lower as Q3 2026 earnings lag revenue growth
Published on 08/17/2026 at 17:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Schott Pharma AG & Co. KGaA (ISIN DE000A3ENQ51) stock is trading slightly weaker on August 17, 2026, as investors weigh strong revenue growth in the third quarter of 2026 against a noticeable decline in earnings and ongoing margin pressure.
Per a recent overview of the company’s latest results dated August 16, 2026, Schott Pharma reported that in the third quarter of fiscal 2026, sales increased to EUR 281.76 million while net income fell to EUR 38.83 million compared with the same quarter a year earlier, underscoring the tension between top-line expansion and profitability. Over the first nine months of the fiscal year, revenues rose to EUR 769.83 million, but earnings per share from continuing operations slipped to EUR 0.68, a trend that has prompted closer scrutiny of the company’s operating leverage and cost base.
Q3 2026 results highlight mixed earnings picture
The most recent third-quarter 2026 figures present a mixed picture for Schott Pharma, with revenue momentum offset by weaker earnings. In the quarter, sales rose to EUR 281.76 million, indicating that demand for the company’s pharmaceutical packaging and delivery systems remains robust in its core markets. At the same time, net income declined to EUR 38.83 million versus the prior-year quarter, pointing to higher costs, margin compression, or a less favorable product and customer mix.
Over the first nine months of fiscal 2026, Schott Pharma’s cumulative revenue climbed to EUR 769.83 million, confirming that the company is successfully expanding its business volume across key segments such as vials, syringes, and polymer-based solutions. However, earnings per share from continuing operations for the nine-month period came in at EUR 0.68, down from the level reported a year earlier, indicating that profitability is not keeping pace with revenue growth and that the company must either improve pricing power or further optimize its cost structure to sustain earnings.
Valuation and consensus context
The same nine-month and third-quarter 2026 data set is used to derive an equity valuation framework that implies a fair value of EUR 20.43 per share for Schott Pharma based on analyst forecasts. Against the current market price referenced in that analysis, this fair value represents a downside of 7 percent, suggesting that, based on the modelled trajectory of revenue and earnings, the shares are trading at a premium to the calculated intrinsic value.
According to that assessment, meeting the fair-value scenario would require Schott Pharma to achieve yearly revenue growth of 6.6 percent and an earnings increase of EUR 47 million from a present earnings base of EUR 142.8 million. This requirement underlines that investors are effectively betting on continued robust top-line expansion and a clear improvement in profitability. For equity holders, the key question is whether the company can convert its growing revenue into proportionately higher earnings, given the evidence from the latest quarter that margins are under pressure.
Same-day share performance and trading data
On August 17, 2026, Schott Pharma shares are quoted on the home market in Europe with a modest decline relative to the previous session. A detailed share graph compiled for Western Europe Standard Time shows that at 4:45 p.m. local time on August 17, 2026, the open price and last price for the stock stood at EUR 2.73, with a change in currency of EUR -0.01 and a daily percentage change of -0.18 percent from the prior close. The day’s trading range ran between an intraday high of EUR 2.75 and an intraday low of EUR 2.73, with 19,452 shares changing hands, illustrating a relatively tight price band and moderate liquidity in the session.
Over the custom period spanning from June 17, 2025, to June 17, 2026, the same share-graph data set indicates that the first price of the period was EUR 3.03, while the last price at the end of the period was EUR 2.66. This represents a decline in currency of EUR 0.38 and a percentage change of -12.38 percent across that twelve-month window. During that period, the total number of shares traded came to 51,951,691, highlighting a meaningful turnover even as the price trend was negative. The historical comparison of EUR 3.03 at the start of the period versus EUR 2.66 at the end underscores that Schott Pharma’s share price has been under downward pressure over the last year, even as revenues have been rising, consistent with investor concern around earnings quality.
Sustainability initiative and long-term positioning
Beyond quarterly numbers and daily price moves, Schott Pharma has been expanding its strategic initiatives, including sustainability in its supply chain. A fresh item on August 17, 2026 discusses the company’s adoption of an absolute Scope 3 climate target, which covers upstream and downstream emissions associated with its products and operations. Setting such a Scope 3 goal signals that Schott Pharma is aiming to reduce its overall value-chain emissions in line with climate benchmarks, which could be important both for regulatory compliance and for winning business from large pharmaceutical clients that increasingly factor environmental performance into supplier selection.
This sustainability push complements the company’s efforts in product innovation and potentially supports its commercial prospects in markets where environmental standards and reporting are becoming more stringent. For investors, the linkage between sustainability targets and future revenue or cost outcomes is key: reducing emissions may entail investment upfront, but it can also generate efficiencies and strengthen customer relationships, which in turn may support revenue growth and margin resilience over time.
Product focus - TOPPAC infuse polymer syringe
One representative product illustrating Schott Pharma’s innovation strategy is the TOPPAC infuse next-generation polymer syringe, which has been showcased with blister-free, recyclable packaging. The polymer-based design is tailored for use in complex drug delivery settings, and the move toward recyclable, blister-free packaging aligns with both hospital needs and broader environmental objectives. The product targets segments where drug stability, safety, and accurate dosing are critical, making material and design choices central to performance.
By advancing such polymer syringe solutions, Schott Pharma positions itself to serve biopharmaceutical companies and healthcare providers looking for reliable, high-performance delivery systems that also meet sustainability and regulatory requirements. The focus on recyclable packaging can help healthcare systems reduce waste, while blister-free formats may improve handling efficiency and reduce materials usage. These product characteristics dovetail with the company’s broader growth story, where innovation in packaging and delivery technology supports revenue expansion and reinforces long-term customer relationships.
Closing stock view
As of August 17, 2026, based on the Western Europe Standard Time quote at 4:45 p.m., Schott Pharma stock closed at EUR 2.73, with the day’s move showing a small decline of EUR 0.01 or 0.18 percent, within an intraday range between EUR 2.73 and EUR 2.75.
Against the backdrop of rising third-quarter 2026 revenue to EUR 281.76 million, but declining net income to EUR 38.83 million and nine-month earnings per share of EUR 0.68, the modest share-price softness reflects investor caution around the company’s ability to translate its growth in sales into sustained earnings and margin improvement.
